MedX Announces Final Acceptance of Issuance of Series II Convertible Loan Notes
21 Junio 2022 - 7:33AM
Business Wire
MedX Health Corp. (“MedX” or the “Company”)
(TSXV: MDX), a global leader in teledermatology, is pleased
to announce that it has received final Acceptance from the TSX
Venture Exchange in respect of the Closing of the placement of
Series II Convertible Notes that took place on March 21, 2022, and
which comprised issuance of 20 Series II Convertible Notes, and
raised a total of $1 Million. That Closing was originally announced
in the Company’s Press Release dated March 22, 2022.
The Series II Convertible Notes bear interest at 8% per year,
payable Half-yearly, and will mature on December 31, 2026 (the
“Maturity Date”). The Series II Convertible Notes may be
converted, at the option of the Holder, into units at $0.10 per
unit (“Series II Unit”) at any time until the Maturity Date.
Each Series II Unit will be comprised of One (1) fully paid Common
Share and One-half (1/2) of a Series II Share Purchase Warrant.
Each whole Series II Share Purchase Warrant will be exercisable to
purchase One (1) further Common Share at the price of $0.15,
exercisable for a period expiring on the Series II Maturity Date.
Additionally, the Company will have the right to force redemption
of any Series II Convertible Note(s) then outstanding, on the date
that is thirty days after the date of the notice (“Redemption
Date”), exercisable at any time after January 1, 2025, and
provided that the Company’s common shares have closed at a price of
$0.30 or above for thirty consecutive trading days immediately
preceding the date of the Notice exercising the right, subject to
the right of the Holder(s) of the Series II Convertible Note(s) to
exercise the Conversion Right prior to the Redemption Date. In
connection with the Closing on March 21, 2022, the Company paid
$64,000 in cash commissions and issued 177,778 agent’s warrants
(“Agent’s Warrant(s)”). Each Agent’s Warrant, which is
non-transferable, is exercisable at the price of $0.09 to acquire a
unit comprised of one common share and one-half (1/2) of a
non-transferable Agent’s share purchase warrant. Each whole Agent’s
share purchase Warrant will be exercisable to purchase one common
share at the price of $0.18. The Agent’s Warrants, and any
underlying Agent’s share purchase warrants, will expire, if
unexercised, on the date that is two years subsequent to the date
of issue of the original Agent’s Warrant(s). All the securities
issued on the March 21, 2022 Closing are restricted from trading
prior to July 21, 2022.
About MedX Health Corp.
MedX, headquartered in Ontario, Canada, is a leading medical
device and software company focused on skin health with its
SIAscopy® on DermSecure® telemedicine platform, utilizing its
SIAscopy® technology. SIAscopy® is also imbedded in its products
SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its
ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate®
include hand-held devices that use patented technology utilizing
light and its remittance to view suspicious moles and lesions up to
2mm beneath in a pain-free, non-invasive manner. Its patented
software then creates real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within
seconds. These products are cleared by Health Canada, the U.S. Food
and Drug Administration, the Therapeutic Goods Administration and
Conformité Européenne for use in Canada, the U.S., Australia, New
Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This Media Release may contain forward-looking statements,
which reflect the Company's current expectations regarding future
events. The forward-looking statements involve risks and
uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621005504/en/
Bill Mitoulas, Investor Relations MedX Health Corp. bill@medxhealth.com +1-416-479-9547
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024